Add BrightSurf on Google Email

Can we target the immune system to treat endometriosis?

A study published in Advanced Science reveals that TREM2+ macrophages contribute to immune dysfunction in endometriosis, compromising CD8+ T cell and NK cell cytotoxic behavior. Researchers identified TREM2 as a potential therapeutic target, suggesting new avenues for developing non-hormonal therapies for endometriosis.

SourceWiley·JournalAdvanced Science·DateNov 12, 2026

New drug combination improves survival in patients with muscle-invasive bladder cancer

A new treatment approach combining immunotherapy with targeted cancer drug enfortumab vedotin improves survival in patients with muscle-invasive bladder cancer. The treatment reduces the risk of death by 42% and cancer recurrence or progression by 49% in patients unable to receive standard chemotherapy.

SourceUniversity of California - Los Angeles Health Sciences·JournalNew England Journal of Medicine·DateNov 9, 2026

Making tumors more responsive to immunotherapy

Researchers have discovered how reprogrammed cancer cells can promote the formation of immune cells clusters that help coordinate the immune response, leading to better treatment outcomes for patients. The study's findings suggest that cell reprogramming could become a way to make tumors more responsive to immunotherapy.

SourceLund University·JournalImmunity·TypeExperimental study·DateNov 6, 2026

A third of babies have peanut allergy diagnosis removed

A national program in Australia discovered that over 35% of infants initially diagnosed with a peanut allergy could safely have the diagnosis removed after undergoing an oral food challenge. This finding has significant implications for how Australia's healthcare system approaches infant food allergies.

SourceMurdoch Childrens Research Institute·JournalThe Journal of Allergy and Clinical Immunology In Practice·TypeObservational study·DateNov 4, 2026

Interleukin-33 alleviates the immunosuppressive tumor microenvironment and enhances anti–PD-L1 immunotherapy efficacy in hepatocellular carcinoma

This study demonstrates that interleukin-33 alleviates the immunosuppressive tumor microenvironment in hepatocellular carcinoma, activating the STING/IRF axis and increasing functional CD8⁺ T cells. Combining IL-33 with anti-PD-L1 therapy synergistically reduces tumor burden and boosts anti-tumor immunity in vivo.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeExperimental study·DateOct 30, 2026

Activating cancer-fighting protein could make T-cell immunotherapies more effective, study finds

Researchers at UCLA Health Jonsson Comprehensive Cancer Center identified a new strategy to strengthen immune cells and improve their ability to kill cancer cells. Temporarily activating p53, a protein that prevents cancer, helps engineered immune cells resist exhaustion and improve their ability to kill tumor cells.

SourceUniversity of California - Los Angeles Health Sciences·JournalFrontiers in Immunology·DateOct 29, 2026

Immune system protein is a cancer killer on its own, new study shows

A new study published in Cell reveals that perforin, a protein made by T cells and NK cells, can induce ferroptosis in tumor cells, a previously unknown mechanism of cell death. This discovery could have significant implications for understanding how cancers are killed by immune cells and could lead to new avenues for immunotherapy.

SourceMichigan Medicine - University of Michigan·JournalCell·TypeExperimental study·DateOct 29, 2026

Targeting the gut-liver axis: New review explores microbial modulation to enhance immunotherapy in hepatocellular carcinoma

A new review examines how gut microbiota and metabolites reshape liver immunity and propose strategies to overcome immunotherapy resistance. The review discusses four major directions of gut microbiota intervention, including probiotics, fecal microbiota transplantation, engineered bacteria, and metabolite-based interventions.

SourceImmunity & Inflammation·JournalImmunity & Inflammation·TypeSystematic review·DateOct 21, 2026

Curbing the neutrophil surge: New treatment offers hope for autoimmune diseases

Researchers from the University of Osaka have uncovered the first steps in the development of ANCA-associated glomerulonephritis, a kidney disease triggered by ANCAs. They found that injured kidney cells send signals attracting immune cells, including neutrophils, which drive inflammation in the early stages.

SourceImmunology Frontier Research Center (IFReC) - The University of Osaka·JournalJournal of Experimental Medicine·TypeExperimental study·DateOct 19, 2026

Structurally guided therapy shows promise for patients with specific EGFR-mutated lung cancer in Phase 1b trial

The Phase 1b FURTHER trial revealed that firmonertinib achieved durable antitumor activity in patients with EGFR PACC-mutated non-small cell lung cancer, with 43% and 68% objective response rates at 160mg and 240mg daily doses, respectively. Patients with complete clearance of EGFR PACC mutations from their blood experienced higher res...

Chinese Medical Journal article review synthesizes molecular mechanisms, current therapeutics, and emerging strategies in esophageal cancer

This comprehensive review synthesizes molecular mechanisms, current therapeutics, and emerging strategies in esophageal cancer. The findings highlight breakthroughs in immunotherapy and promising future directions in targeted therapies.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateOct 14, 2026

In situ generation of NKG2D CAR T/NK cells via a tumor-targeted lipoplex for enhancing cancer immunotherapy

Researchers developed a GRM4-targeted lipoplex to generate NKG2D CAR T/NK cells within triple-negative breast cancer, eliminating the need for cells to reach their target. The approach improved safety and antitumor efficacy, increasing CD8+ T cell infiltration, NK cell activation, and tumor growth inhibition.

SourceScience China Press·JournalScience Bulletin·TypeExperimental study·DateOct 13, 2026

Heavily immunosuppressed patients undergoing anticancer immunotherapy face increased risk of severe infections

A retrospective analysis of 20,000 patient records found that patients receiving immunotherapy and multiple immunosuppressive therapies were at higher risk of severe infections. Treatment with multiple immunosuppressive therapies was associated with increased rates and severity of infection.

SourceMass General Brigham·JournalJournal of the National Comprehensive Cancer Network·TypeObservational study·DateSep 24, 2026

AI model uses routine imaging to identify patients at risk for serious treatment-induced lung inflammation

Researchers developed an AI model that uses routine chest CT scans to identify patients at risk of pneumonitis, a potentially life-threatening form of lung inflammation. The model, called CIPHER, achieved high predictive power and maintained strong performance despite differences in patient populations and imaging protocols.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalJournal for ImmunoTherapy of Cancer·DateSep 24, 2026

Researchers uncover dual role of B7-H3 in tumor immune suppression

Researchers identified a previously unknown pathway that prostate tumors leverage to suppress the immune system, reshaping the tumor microenvironment to resist treatment. Combining B7-H3-targeted therapy with MEK inhibition improved antitumor responses and prolonged survival in preclinical models of castration-resistant prostate cancer.

Professor Dong Zhang’s team at Beijing Chao-Yang Hospital reveals a new mechanism underlying the potent anti-tumor activity of TCRαβ+CD4-CD8- double-negative T cells

Research by Professor Dong Zhang's team identifies IFITM1 as a key regulator of mitophagy, essential for maintaining the anti-tumor activity of double-negative T cells. This mechanism provides a promising strategy for optimizing TCRαβ+CD4-CD8- T cell therapies.

SourceScience China Press·JournalScience China Life Sciences·DateSep 22, 2026

Building big with DNA gets a software upgrade

Researchers have developed a computational framework to design and fabricate crisscross DNA megastructures, expanding accessibility to DNA nanotechnology. This breakthrough enables the construction of complex structures with precise control, opening up new avenues for applications in fields like optics, immunology, and tissue engineering.

SourceWyss Institute for Biologically Inspired Engineering at Harvard·JournalNature Communications·TypeComputational simulation/modeling·DateSep 16, 2026

Pembrolizumab plus chemotherapy for cervical cancer

The study confirms the durability of benefit for pembrolizumab plus chemotherapy as a first-line standard-of-care option for recurrent and metastatic cervical cancer. This treatment regimen has been shown to provide a significant advantage over traditional chemotherapy in patients with this type of cancer.

SourceJAMA Network·JournalJAMA Oncology·DateSep 10, 2026

Why does the immune system sometimes help tumors grow?

Salk Institute researchers have discovered a novel pathway that links chronic interferon II exposure to mitochondrial dysfunction, leading to immunosuppression and enhanced tumor growth. By blocking prostaglandin E2, they found a viable target to restore immune system function and combat immunotherapy resistance.

SourceSalk Institute·JournalScience·DateSep 10, 2026

Tumor-infiltrating lymphocyte therapy offers a promising approach for treating solid tumors

Tumor-infiltrating lymphocyte therapy has shown potential in several types of solid tumors, including metastatic melanoma, breast cancer, and ovarian cancer. Despite challenges, the approach has favorable clinical outcomes, and researchers are exploring combination strategies and advanced technologies to improve treatment durability.

SourceImpact Journals LLC·JournalOncotarget·TypeNews article·DateAug 31, 2026

Rapid development of immunotherapy for gynecological tumors: How to achieve overtaking on the curve?

Immunotherapy for gynecological tumors offers durable responses and survival benefits, but complex immune evasion mechanisms and tumor microenvironment pose challenges. Current treatment options, such as ICIs and adoptive cell therapy, show promise, but precision immunotherapy is needed to improve patient outcomes.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateAug 31, 2026